Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Neoadjuvant AGEN1884 Plus AGEN2034 in Combination With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy

NCT04430036 is registered in ClinicalTrials.gov with The University of Texas Health Science Center at San Antonio as lead sponsor.

NCT NCT04430036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04430036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Neoadjuvant AGEN1884 Plus AGEN2034 in Combination With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy
Lead sponsor
The University of Texas Health Science Center at San Antonio
Phase
Phase 2
Overall status
Terminated
Start date
October 14, 2020
Completion date
March 14, 2022
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

urinary bladder neoplasms